Abstract
Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients were included. The overall pooled sensitivity and specificity were 0.70 and 0.86, respectively. The LR+ was 3.85, the LR- was 0.34 and DOR was 15.84. The SROC curve with an AUC of 0.88 indicated a relatively high accuracy of LB for molecular characterization of PC. The concordance rate of all mutations detected by multi-genes panels was 31.9%. LB can serve as surrogate for tissue in the molecular profiling of PC, because of its relatively high sensitivity, specificity and accuracy. It represents a unique opportunity to be further explored towards its introduction in clinical practice and for developing new precision medicine approaches against PC.
| Original language | English (US) |
|---|---|
| Article number | 1152 |
| Journal | Cancers |
| Volume | 11 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2019 |
Fingerprint
Keywords
- CfDNA
- Circulating tumor cells (CTC)
- Liquid biopsy
- Pancreatic cancer
- Precision medicine
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer : A meta-analysis towards precision medicine. / Luchini, Claudio; Veronese, Nicola; Nottegar, Alessia; Cappelletti, Vera; Daidone, Maria G.; Smith, Lee; Parris, Christopher; Brosens, Lodewijk A.A.; Caruso, Maria G.; Cheng, Liang; Wolfgang, Christopher L.; Wood, Laura D.; Milella, Michele; Salvia, Roberto; Scarpa, Aldo.
In: Cancers, Vol. 11, No. 8, 1152, 08.2019.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer
T2 - A meta-analysis towards precision medicine
AU - Luchini, Claudio
AU - Veronese, Nicola
AU - Nottegar, Alessia
AU - Cappelletti, Vera
AU - Daidone, Maria G.
AU - Smith, Lee
AU - Parris, Christopher
AU - Brosens, Lodewijk A.A.
AU - Caruso, Maria G.
AU - Cheng, Liang
AU - Wolfgang, Christopher L.
AU - Wood, Laura D.
AU - Milella, Michele
AU - Salvia, Roberto
AU - Scarpa, Aldo
PY - 2019/8
Y1 - 2019/8
N2 - Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients were included. The overall pooled sensitivity and specificity were 0.70 and 0.86, respectively. The LR+ was 3.85, the LR- was 0.34 and DOR was 15.84. The SROC curve with an AUC of 0.88 indicated a relatively high accuracy of LB for molecular characterization of PC. The concordance rate of all mutations detected by multi-genes panels was 31.9%. LB can serve as surrogate for tissue in the molecular profiling of PC, because of its relatively high sensitivity, specificity and accuracy. It represents a unique opportunity to be further explored towards its introduction in clinical practice and for developing new precision medicine approaches against PC.
AB - Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients were included. The overall pooled sensitivity and specificity were 0.70 and 0.86, respectively. The LR+ was 3.85, the LR- was 0.34 and DOR was 15.84. The SROC curve with an AUC of 0.88 indicated a relatively high accuracy of LB for molecular characterization of PC. The concordance rate of all mutations detected by multi-genes panels was 31.9%. LB can serve as surrogate for tissue in the molecular profiling of PC, because of its relatively high sensitivity, specificity and accuracy. It represents a unique opportunity to be further explored towards its introduction in clinical practice and for developing new precision medicine approaches against PC.
KW - CfDNA
KW - Circulating tumor cells (CTC)
KW - Liquid biopsy
KW - Pancreatic cancer
KW - Precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85073276091&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073276091&partnerID=8YFLogxK
U2 - 10.3390/cancers11081152
DO - 10.3390/cancers11081152
M3 - Review article
C2 - 31405192
AN - SCOPUS:85073276091
VL - 11
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 8
M1 - 1152
ER -